leisure time -WSS

leisure time

author：leisure time 2025-10-01 15:29:27 - browse：698

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Change Healthcare cyberattack prompts Medicare loan program

hotspot

WSS

Departing Stanford president retracts two papers

Complete sequence of Y chromosome published for first time

Change Healthcare payments predicted restored March 15

Amylyx ALS drug fails large clinical trial

Air quality improving but still lags in Black, Hispanic communities

Psilocybin's anti

focus

leisure time

leisure time

New air purifier tech could be key to improving indoor air quality

As pharma fights Medicare drug negotiation, hospitals, docs silent

Hepatitis C has a cure — but many Americans still lack access to it

UnitedHealth quietly bought dozens of outpatient centers

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

RSV shot was 90% effective at preventing hospitalizations in kids

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth quietly bought dozens of outpatient centers

ChatGPT in medicine: STAT answers readers' burning questions

AstraZeneca challenges Medicare drug negotiation program

focus

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Change Healthcare cyberattack prompts Medicare loan program

Complete sequence of Y chromosome published for first time

UnitedHealth quietly bought dozens of outpatient centers

Apellis safety probe of eye disease drug centers on injection needle

Novo Nordisk obesity pill bests Wegovy in early trial

leisure time

entertainment

hotspot

explore